Diffusion MRI (dMRI) is a powerful tool to study white matter maturation. In our new preprint, we process and distribute a new resource of >24,000 ABCD dMRI scans using open source tools! We then evaluate how methods shape inferences about development.
🔗 www.biorxiv.org/content/10.6...
✨Excited to share that our new preprint, "Mapping developmental patterns of intrinsic timescale", is now available on bioRxiv!!
📚 doi.org/10.64898/202...
However, our database is living in nature and we could include the optional half doses somewhere in our database in future releases.
Hey Mark! For now, we don't include the supplemental half doses in the metapsy database, given that they were optional. We note whether or not the option was provided in Table 1.
It is important to note that GRADE ratings are meant to indicate the level of confidence that the true treatment effect in routine clinical practice will match the effects seen so far in RCTs. We will continue to update our GRADE report in future versions as more evidence emerges.
However, we believe the high prior MDMA use still has the potential to amplify functional unblinding effects if participants are more familiar with the distinct side effects of MDMA, and more broadly indicates that the trials were not reflective of the general population.
This remains an interesting point of discussion! For our GRADE ratings, we wanted to be cautious with contextualizing the results of the study given the limitations in the field. I agree those findings from the MAPS report are promising.
Team effort with co-first author @parkersingleton.bsky.social, Analiese Lahey, @pimcuijpers.bsky.social, @mathiasharrer.bsky.social, @mntj21.bsky.social, Sandeep Nayak, Eric Strain, @vandyatvandy.bsky.social, David Yaden, Bob Dworkin, @jcobbscott.bsky.social, @ted-satterthwaite.bsky.social
In partnership with metapsy.org, we built an interactive dashboard for exploring the data. Users can:
• Filter studies by characteristics
• Test different analysis parameters
• Test moderators
• Download figures and reports
Dashboard: metapsy.org/sypres/mdma-ptsd
Our database includes 60+ effect sizes, encompassing all PTSD outcomes and timepoints reported by arm in each of the 6 RCTs included. This database can be downloaded from our website (sypres.io) or imported directly into R using the metapsyData package.
Here, MDMA showed a greater reduction in PTSD symptoms compared to control conditions, with a pooled Hedges’ g = -0.71. But important caveats: small studies, functional unblinding challenges, and a low certainty rating with the GRADE approach should contextualize our results.
This is the second installation in our sypres.io initiative featuring:
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data
Psychedelic science has experienced the benefits and drawbacks of hype. However, new results are rarely contextualized in the historical body of evidence in an accessible manner. We need more robust, living evidence synthesis that is visible and accessible to all stakeholders.
🍄 Our new living systematic review and meta-analysis on MDMA for PTSD is now live on medRxiv. Here's what we found and how we built upon our open science infrastructure to support it 🧵
www.medrxiv.org/content/10.6...
🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out now in Nature Mental Health. Here's what we found and the open science infrastructure we built to support it 🧵
Open-Access Link: rdcu.be/fbU5V
#PenNLINC is recruiting a clinical coordinator / lab manager!!! Looking for someone who is good with both people + code, wants to learn to acquire + analyze imaging data. Alumni in this role have written 1st author papers + gone to top grad programs.
Website: www.pennlinc.io
Job: bit.ly/4ojvCir
An Open, Fully-processed, Longitudinal Data Resource to Study Brain Development and Transdiagnostic Executive Function www.biorxiv.org/content/10.1101/2025.11....
Huge shoutout to @ted-satterthwaite.bsky.social @goliashf.bsky.social and the entire team at @pennlinc.bsky.social behind this data resource!
🌐 Explore the Resources:
• OpenNeuro dataset with links to derived data repositories: openneuro.org/datasets/ds0...
• Full preprint: www.biorxiv.org/content/10.1...
• GitHub repository: github.com/PennLINC/tra...
✅ We used open-source, containerized, reproducible processing pipelines and software for all image processing and analysis: This includes HeuDiConv and CuBIDS for organization and curation of BIDS images; and BABS, fMRIPrep, XCP-D, QSIPrep, QSIRecon, and ASLPrep for image processing.
🔬 Throughout the dataset, we maintain an open science infrastructure:
✅ Public sharing of data and code: All raw data and fully-processed derived data are anonymized and publicly shared on OpenNeuro. All custom code and quality control recommendations are publicly shared on GitHub.
📊 Our dataset also includes neuroimaging data:
• Raw imaging data and fully-processed derived data from structural MRI, diffusion MRI, n-back task fMRI, resting-state fMRI, arterial spin-labeled MRI
• Quality control recommendations for imaging data
📊 Our dataset includes phenotypic information:
• Phenotypic data from multiple cognitive tasks focused on EF from the Penn Computerized Neurocognitive Battery (CNB)
• Clinical diagnostic data from clinical interviews
Penn LEAD combines longitudinal multi-modal imaging data with rich clinical and cognitive phenotyping. These data include 225 imaging sessions from 132 individuals who are typically developing or meeting criteria for attention-deficit hyperactivity disorder (ADHD) or the psychosis-spectrum (PS).
🧠I am excited to announce that our manuscript introducing a new data resource – PennLEAD (Penn Longitudinal Executive functioning in Adolescent Development) – is now available on bioRxiv. Below are some details highlighting our data resource🧵funded by NIMH R01MH113550
www.biorxiv.org/content/10.1...
SYPRES (Synthesis of Psychedelic Research Studies) logo
🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵
www.medrxiv.org/content/10.1...